Jorden David Emerson's Form 4 filing
Nuo Therapeutics, Inc. (AURX) · filed Dec 3, 2025
- Accession no.
- 0001437749-25-036821
- Filed
- Dec 3, 2025
- Trade date
- Nov 28, 2025
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $300.0K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jorden David EmersonCIK 0001313516 | Director, Officer (CEO/CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | SSaleDisposed | −200,000 | $1.50 | −$300,000 | 1,946,755 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.